Form 4: BridgeBio CEO Sells Shares After RSU Vesting

Sentiment:

Insider Transaction Report 16 December 2025 6:27 PM

BridgeBio Pharma CEO Neil Kumar reported the vesting of Restricted Stock Units and subsequent sale of common stock, partially to cover tax obligations, under a pre-arranged 10b5-1 plan.

Summary

Neil Kumar, CEO and Director of BridgeBio Pharma, Inc., reported transactions involving the company's common stock and Restricted Stock Units (RSUs).
On December 12, 2025, 60,975 Restricted Stock Units (RSUs) vested, converting into an equal number of common shares.
Concurrently, 30,964 shares of common stock were disposed of at an implied price of $75.15 per share to satisfy tax obligations related to the RSU vesting.
On December 15, 2025, Mr. Kumar sold a total of 30,011 shares of common stock (28,311 shares and 1,700 shares) through two separate transactions.
The 28,311 shares were sold at a weighted average price of $74.5997, with prices ranging from $74.12 to $75.11 per share.
The 1,700 shares were sold at a weighted average price of $75.2412, with prices ranging from $75.13 to $75.49 per share.
These sales were executed pursuant to a Rule 10b5-1 sales plan adopted by Mr. Kumar on March 31, 2025.
Following these transactions, Mr. Kumar directly beneficially owns 228,776 shares of common stock and 60,976 Restricted Stock Units.
Indirect beneficial ownership includes 755,686 shares through the Kumar Haldea Family Irrevocable Trust and 4,558,447 shares through the Kumar Haldea Revocable Trust, for which Mr. Kumar is a co-trustee.

Sentiment

Score: 5

Explanation: This is a routine insider transaction involving the vesting of Restricted Stock Units and subsequent sales under a pre-arranged 10b5-1 plan. It does not inherently signal a positive or negative change in the company's operational or financial health.

Positives

The vesting of 60,975 Restricted Stock Units represents a successful milestone for the CEO's compensation plan.
The transactions were conducted under a pre-arranged Rule 10b5-1 plan, indicating planned personal financial management rather than reactive trading.

Negatives

The sale of 30,011 shares by the CEO, even under a 10b5-1 plan, could be perceived by some investors as a reduction in insider holdings.

Future Outlook

The remaining underlying shares of the Restricted Stock Units are scheduled to vest on December 12, 2026, contingent upon the Reporting Person's continued service with BridgeBio Pharma or its subsidiaries.

Management Comments

The transactions were effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.

Industry Context

Insider transactions, such as RSU vesting and subsequent sales, are common occurrences for executives in publicly traded companies across all industries. The use of a Rule 10b5-1 plan is a standard practice for insiders to manage their equity holdings and personal finances while complying with insider trading regulations.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Insider Trading Plan	The Reporting Person's sales were conducted under a Rule 10b5-1 sales plan, adopted on March 31, 2025, which allows insiders to set up a pre-arranged plan to buy or sell company stock.	03/31/2025	This demonstrates adherence to corporate governance best practices by mitigating concerns about insider trading based on material non-public information, as the plan was established in advance.

Related Party Transactions

Indirect beneficial ownership of common stock is held through the Kumar Haldea Family Irrevocable Trust and the Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership except to the extent of pecuniary interest.

Stakeholder Impact

Shareholders: The transactions are routine for an executive and are unlikely to have a significant direct impact on the company's share price or long-term value. The sales are part of personal financial planning, not necessarily a reflection of company performance.
Employees: No direct impact on employees is indicated by this filing.

Next Steps

The remaining underlying shares of the Restricted Stock Units are scheduled to vest on December 12, 2026.

Key Dates

Date	Description
03/31/2025	Rule 10b5-1 sales plan adopted by the Reporting Person.
12/12/2025	Date of RSU vesting and acquisition of common stock, and disposition of shares for tax withholding.
12/15/2025	Date of common stock sales.
12/12/2026	Remaining underlying shares of RSUs are scheduled to vest, subject to continued service.

Recommendation

hold

This Form 4 details routine insider transactions (RSU vesting, tax withholding, and sales under a pre-arranged 10b5-1 plan) by the CEO. Such transactions are common for executives for personal financial planning and do not typically indicate a change in the company's fundamental outlook or warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as this filing does not provide new information to alter the existing investment thesis.

Keywords

BridgeBio Pharma, BBIO, Neil Kumar, Insider Trading, Stock Sale, RSU Vesting, 10b5-1 Plan, Common Stock

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.